COLL Quote, Financials, Valuation and Earnings

Insmed has a net margin of 5.86% compared to Collegium Pharmaceutical's net margin of -236.04%. Collegium Pharmaceutical's return on equity of 42.3% beat Insmed's return on equity of --.

Collegium Pharmaceutical has a consensus price target of --, signalling upside risk potential of 43.27%. On the other hand Insmed has an analysts' consensus of $88.25 which suggests that it could grow by 26.5%. Given that Collegium Pharmaceutical has higher upside potential than Insmed, analysts believe Collegium Pharmaceutical is more attractive than Insmed.

Collegium Pharmaceutical has a beta of 0.798, which suggesting that the stock is 20.242% less volatile than S&P 500. In comparison Insmed has a beta of 1.103, suggesting its more volatile than the S&P 500 by 10.328%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $159.3M, which are larger than Insmed quarterly revenues of $93.4M. Collegium Pharmaceutical's net income of $9.3M is higher than Insmed's net income of -$220.5M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 12.66x while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 2.26x versus 32.03x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Pulmonx has a net margin of 5.86% compared to Collegium Pharmaceutical's net margin of -69.38%. Collegium Pharmaceutical's return on equity of 42.3% beat Pulmonx's return on equity of -51.95%.

Collegium Pharmaceutical has a consensus price target of --, signalling upside risk potential of 43.27%. On the other hand Pulmonx has an analysts' consensus of -- which suggests that it could grow by 73.21%. Given that Pulmonx has higher upside potential than Collegium Pharmaceutical, analysts believe Pulmonx is more attractive than Collegium Pharmaceutical.

Collegium Pharmaceutical has a beta of 0.798, which suggesting that the stock is 20.242% less volatile than S&P 500. In comparison Pulmonx has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pulmonx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Pulmonx pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $159.3M, which are larger than Pulmonx quarterly revenues of $20.4M. Collegium Pharmaceutical's net income of $9.3M is higher than Pulmonx's net income of -$14.1M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 12.66x while Pulmonx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 2.26x versus 3.37x for Pulmonx. Usually stocks with elevated PS ratios are considered overvalued.

PROCEPT BioRobotics has a net margin of 5.86% compared to Collegium Pharmaceutical's net margin of -35.93%. Collegium Pharmaceutical's return on equity of 42.3% beat PROCEPT BioRobotics's return on equity of -37.42%.

Collegium Pharmaceutical has a consensus price target of --, signalling upside risk potential of 43.27%. On the other hand PROCEPT BioRobotics has an analysts' consensus of $102.75 which suggests that it could grow by 23.01%. Given that Collegium Pharmaceutical has higher upside potential than PROCEPT BioRobotics, analysts believe Collegium Pharmaceutical is more attractive than PROCEPT BioRobotics.

Collegium Pharmaceutical has a beta of 0.798, which suggesting that the stock is 20.242% less volatile than S&P 500. In comparison PROCEPT BioRobotics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. PROCEPT BioRobotics pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $159.3M, which are larger than PROCEPT BioRobotics quarterly revenues of $58.4M. Collegium Pharmaceutical's net income of $9.3M is higher than PROCEPT BioRobotics's net income of -$21M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 12.66x while PROCEPT BioRobotics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 2.26x versus 21.45x for PROCEPT BioRobotics. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of 5.86% compared to Collegium Pharmaceutical's net margin of -17.95%. Collegium Pharmaceutical's return on equity of 42.3% beat RxSight's return on equity of -14.78%.

Collegium Pharmaceutical has a consensus price target of --, signalling upside risk potential of 43.27%. On the other hand RxSight has an analysts' consensus of $58.00 which suggests that it could grow by 65.48%. Given that RxSight has higher upside potential than Collegium Pharmaceutical, analysts believe RxSight is more attractive than Collegium Pharmaceutical.

Collegium Pharmaceutical has a beta of 0.798, which suggesting that the stock is 20.242% less volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $159.3M, which are larger than RxSight quarterly revenues of $35.3M. Collegium Pharmaceutical's net income of $9.3M is higher than RxSight's net income of -$6.3M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 12.66x while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 2.26x versus 10.32x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.